MNMD - Mind Medicine Corp Total Debt to Capital

Public company logo of Mind Medicine (MNMD)

How should complex mental disorders be treated? Mind Medicine (MNMD) is developing breakthrough drugs at the intersection of neuroscience. This chart illustrates the debt-to-equity ratio as calculated by the GURU.Markets system, where 0.31 captures the value of this parameter. The solution lies in a future patent monopoly coupled with low production costs, which is further supported by strong investor confidence in the company's innovations.

MNMD: MindMed Total Debt to Capital 07/04/2022 - 01/15/2026

Analytical breakdowns for Mind Medicine

- price and consensus price forecast:
Price Chart MindMed|MNMD - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization MindMed|MNMD - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share MindMed|MNMD - Book Capitalization|Market Value to Book Value Ratio mindmed.co|MNMD - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Mind Medicine|MNMD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Mind Medicine|MNMD - Company Aggregate Debts|Debt to Book Value MindMed|MNMD - Company Long-Term Loans and Borrowings|Company Short-Term Debt MindMed|Quick Liquidity mindmed.co
- earnings and valuation multiples information:
MNMD - Net Financial Result
Basic company analysis:MindMed
Core merchandise of Mind Medicine Corp

The financial stability of Mind Medicine (MNMD) is determined by the balance between raised funds and proprietary assets. This metric is calculated as the ratio of total liabilities to equity, reflecting the share of debt financing within the business structure. This coefficient measures the organization's risk of dependence on creditors. For a biotechnology startup without current revenue, this is a critical indicator of solvency. By analyzing the changing proportion of total debt to equity, an investor assesses the probability of a cash crunch prior to the commercialization of drugs.

Competitor analysis for Mind Medicine

Debt to Equity Alkermes|Avadel Pharmaceuticals PLC - Aggregate Debt to Equity|Total Debt to Capital ATAI|GHRS (GH Research Group) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital CMPS (COMPASS Pathways plc)|Total Debt to Capital lbpharma.us LBRX|DRUG - Debt to Equity|All Debt to Shareholders' Equity Ratio VNDA (Vanda Pharma)|cybin.com (CYBN) - Debt to Equity|Total Debt to Equity Ratio Alto Neuroscience Corp|NRXP (NRx Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital Cingulate Corp|Total Debt to Equity Ratio SILO (Silo Pharma, Inc.)|CPHI (chinapharmaholdings.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Clearmind Medicine CMND|PBM (Psyence Bio) - Aggregate Debt to Equity|SPRC - Debt to Equity|Total Debt to Capital Coefficient seelostherapeutics.com SEEL|VRPX (virpaxpharma.com) - Total Debt to Equity Ratio|Debt to Capital Karuna Therapeutics Inc (KRTX)